Delivery Order SPE2DR25D9223-SPE2DR26FFAE5
Award Date 2/12/26
Potential Completion Date 2/13/26
Potential Value $6.1K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency issued a $36,857.52 delivery order to DMS Pharmaceutical Group Inc. on February 11, 2026, for Fasenra (reslizumab) 30 mg/mL under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is a Defense Logistics Agency indefinite delivery contract authorizing firm fixed-price delivery orders for pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 5, 2026, for $2,493.75 to supply Fasenra (reslizumab) 30 mg/mL under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). DMS Pharmaceutical Group Inc. is a woman-owned small business. The order is issued under the PPV-G GEN V, a Defense Logistics Agency single-award indefinite delivery contract with a $499.999 billion ceiling and ultimate completion date of December 31,...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, on February 9, 2026, with a ceiling value of $12,285.84 for supply of Fasenra (reslizumab) 30 mg/mL. The order is issued under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a DLA indefinite delivery contract that authorizes firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, biologics, and medical consumables to...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 10, 2026, with a ceiling value of $6,142.92 for supply of FASENRA (reslizumab) 30 mg/mL, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is a Defense Logistics Agency indefinite delivery contract authorizing firm fixed-price delivery orders for pharmaceutical products and medical consumables to support Department of Defense healthcare operations...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 6, 2026, for FASENRA (reslizumab) 30 mg/mL pharmaceutical supply, with a ceiling value of $12,285.84, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is a Defense Logistics Agency indefinite delivery contract authorizing firm fixed-price delivery orders for branded and generic prescription drugs, over-the-counter medications, biologics, and medical...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, on February 12, 2026, with a ceiling value of $6,142.92 for FASENRA (reslizumab) 30 mg/mL pharmaceutical supply. The delivery order is issued under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a single-award indefinite delivery contract with a $499.999 billion ceiling and performance through December 31, 2036. PPV-G GEN V...
- The Defense Logistics Agency issued a $18,428.76 delivery order to DMS Pharmaceutical Group Inc. on February 10, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for Fasenra (benralizumab) 30 mg/mL. PPV-G GEN V is a Defense Logistics Agency pharmaceutical prime vendor program authorizing firm fixed-price delivery orders for branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense healthcare operations...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 11, 2026, with a ceiling value of $6,142.92 for FASENRA (reslizumab) 30 mg/mL, a biologic immunosuppressant pharmaceutical product. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler. This delivery order is issued under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a single-award indefinite...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 9, 2026, with a ceiling value of $29,925.00, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for supply of Fasenra 30 mg/ml syringe. DMS Pharmaceutical Group Inc. is a woman-owned small business. The PPV-G GEN V is a Defense Logistics Agency indefinite delivery contract authorizing firm fixed-price delivery orders for pharmaceutical products and medical consumables to...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 10, 2026, with a ceiling value of $16,149.52, for supply of Fasenra 30 mg/mL under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is a DLA-administered indefinite delivery contract vehicle supporting pharmaceutical supply to Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical...